Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial

RCT (n=947) found that both upadacitinib 15 mg and 30 mg doses were superior to methotrexate for ACR50 response at week 12 (52% and 56% vs 28%, p<0.001). Both doses were also superior in terms of lack of radiographic progression (88% and 89% vs 78%, p<0.001)


Arthritis & Rheumatology